CPT code 82523 – Collagen cross-links testing

Key takeaways

CPT code 82523 covers every collagen cross-link analyte (CTX, NTX, DPD, PYD) under one code, so serum and urine specimens bill the same way.

Medicare coverage comes from National Coverage Determination 190.19, which ties each covered test to a point in antiresorptive treatment.

Medicare pays for one or two baseline tests, a repeat about 3 months into therapy, and another 12 months later. After that, one test a year is the limit.

Most denials trace back to a non-covered ICD-10 pairing, a test ordered outside the frequency schedule, or no documented antiresorptive treatment plan.

Pabau’s claims management software checks eligibility in real time, builds superbills, and returns Claim.MD remittance data, so 82523 denials are easier to catch and correct.

CPT code 82523: Official descriptor and clinical purpose

CPT code 82523 is defined by the American Medical Association (AMA) as “Collagen cross-links, any method.” It reports a test for bone resorption markers, most often ordered to check how a patient with osteoporosis responds to antiresorptive therapy. The phrase “any method” is significant: It means the code covers ELISA, HPLC, immunoassay, and other laboratory techniques. Providers do not need a separate code for each testing platform, and serum and urine specimens bill under the same line item.

82523 sits in the Chemistry subsection (82009-84999) of CPT’s Pathology and Laboratory section. It is not a point-of-care code and is not CLIA-waived, so the performing laboratory must hold appropriate CLIA certification. The CLIA-waived modifier (QW) does not apply here.

What “any method” means in practice

The phrase refers to the analytical chemistry platform rather than to the analyte itself. The lab may run an electrochemiluminescence immunoassay (ECLIA) for serum CTX or a high-performance liquid chromatography (HPLC) assay for urinary DPD. Either way, the code reported is the same: 82523. Practices do not need to determine the lab’s specific method before submitting the claim.

Collagen cross-links analytes, specimens, and testing methods

Four primary analytes are billed under CPT code 82523. Each has a preferred specimen type and a clinical context. The table below maps each marker to its specimen, common method, and clinical use.

Serum CTX is the most frequently ordered analyte because it has a well-established reference range. Robust data also support its use as a surrogate for bisphosphonate response. Urine NTX and DPD remain clinically appropriate alternatives, particularly in patients where fasting serum collection is impractical.

Clinical indications: When to order the test

Payers cover CPT code 82523 only when it is medically necessary. Ordering the test for general bone health screening, without a confirmed diagnosis or a treatment plan, is a frequent cause of denials. Understanding the medical billing workflow for lab tests matters here: The order must be placed with the diagnosis already documented.

Medicare’s National Coverage Determination (NCD) 190.19 sets the covered uses, and payers commonly accept these indications for 82523:

• Osteoporosis monitoring on antiresorptive therapy: The most common covered indication. The patient has a confirmed osteoporosis diagnosis and is starting or receiving an antiresorptive agent (bisphosphonate, denosumab, calcitonin, or a selective estrogen receptor modulator). Medicare follows the NCD 190.19 testing schedule described in the coverage section below.
• Predicting response to antiresorptive therapy: NCD 190.19 covers testing to predict how bone density will respond to FDA-approved antiresorptive therapy in postmenopausal women.
• Paget’s disease of bone (ICD-10 M88.x): Covered to assess the response to treatment.
• Osteoporosis with pathological fracture (ICD-10 M80.x): Covered for monitoring antiresorptive therapy after a fracture.
• Metastatic bone disease (ICD-10 C79.51): Payer-dependent, so check the LCD or policy. Some payers accept it when monitoring bone-targeting agents such as bisphosphonates or denosumab.
• Hyperparathyroidism (ICD-10 E21.x): Payer-dependent, so check the LCD or policy. NCD 190.19 does not list it as a covered use.

Screening a patient with normal bone density and no treatment planned is not a covered indication under Medicare or most commercial policies. Document the diagnosis and the treatment plan in the chart before placing the order.

ICD-10-CM codes that support medical necessity

Pairing CPT code 82523 with the correct ICD-10-CM diagnosis code is required for claim adjudication. Most osteoporosis monitoring claims pair 82523 with M81.0. The table below lists the codes payers commonly accept for 82523, along with codes that are often submitted but rejected.

Check the current covered code list on CMS.gov before submission, because it is updated periodically. Always use the most specific diagnosis code available.

Medicare and commercial payer coverage

Medicare covers CPT code 82523 under National Coverage Determination 190.19, “Collagen Crosslinks, Any Method.” The NCD sets the coverage rules for every Medicare Administrative Contractor (MAC). Local coverage determinations (LCDs) and billing articles only supply the lists of covered ICD-10-CM codes.

Key Medicare coverage parameters under the NCD:

• Testing schedule: NCD 190.19 allows one or two baseline tests, a repeat about 3 months after therapy starts, and another 12 months after that. From then on, testing is limited to once a year unless therapy changes. A test ordered outside this schedule without an advance beneficiary notice (ABN) is likely to be denied.
• Treatment context: The NCD covers monitoring and predicting the response to antiresorptive therapy. The record should name the agent the patient takes, or the plan to start one.
• Ordering provider: The ordering physician must document clinical necessity in the record. The test cannot be self-ordered by the patient.
• ABN requirement: A test may not be covered, for example when the frequency is exceeded or the ICD-10 code is not on the list. To bill the patient, issue a signed ABN before collecting the specimen.

Each covered test falls at a fixed point in treatment, which the schedule below lays out step by step.

Commercial payer policies vary materially. Blue Shield of California, UnitedHealthcare (Louisiana Medicaid), and BCBS Mississippi all publish medical policies on bone turnover markers. Each sets its own frequency limits and covered indications, and some commercial policies allow one test every 3 to 6 months. The UHC Louisiana Medicaid policy applies only to that state’s Medicaid program, not to commercial UHC plans. Always pull the current policy from the payer’s provider portal before ordering.

CPT 82523 Medicare reimbursement rate

CPT code 82523 is paid under the Medicare Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule (PFS). The Centers for Medicare and Medicaid Services (CMS) pays CLFS codes at national limitation amounts, set under the Protecting Access to Medicare Act (PAMA). The schedule applies to independent and hospital outpatient laboratories and is updated every year.

Do not rely on rates published in third-party articles, including this one, for billing purposes. CLFS rates change annually and are the controlling payment amount. Always verify against the current year’s published schedule.

Prior authorization requirements

Medicare does not require prior authorization for most clinical laboratory tests, including 82523. That holds when an eligible provider places the order and the ICD-10 code is on the covered list. Commercial payers are a different story. Conduct insurance eligibility verification before ordering to confirm whether the patient’s plan requires prior authorization for this code.

When prior authorization is required, the documentation package typically includes:

• The specific ICD-10 diagnosis code with supporting clinical notes confirming the diagnosis
• The name, dose, and start date of the current antiresorptive agent
• The ordering physician’s specialty and NPI
• The date and result of the most recent relevant bone density (DXA) scan, if available
• Any previous bone turnover marker results and the clinical rationale for repeat testing

Some commercial payers require the PA request to come from the ordering physician rather than the laboratory. Confirm the submission pathway in the payer’s provider portal before the appointment. Submitting without required authorization is a denial that cannot be appealed on medical necessity grounds alone.

Medical record documentation requirements

Missing or incomplete documentation is a leading cause of 82523 denials, alongside incorrect ICD-10 coding and frequency violations. Maintaining strong medical billing compliance requires the chart to contain all of the following before a claim is submitted.

• Confirmed diagnosis: A documented clinical assessment must support the ICD-10 code. Examples include DXA scan results, radiographic findings, or laboratory evidence of hyperparathyroidism.
• Current antiresorptive agent: Document the drug name, dose, route, and start date, or the planned start date for a baseline test. A prescription printed on the date of service is not sufficient. The medical record must reflect ongoing use.
• Clinical rationale: One to two sentences explaining why the test is being ordered at this point in treatment. For example: “Monitoring response to alendronate initiated 6 months ago; baseline serum CTX obtained at initiation.”
• Ordering provider credentials: The NPI and specialty of the ordering provider must match the claim header. Payers cross-check this against their credentialing database.
• Date of last test: If the test was previously ordered, record the date and result so that frequency-limit compliance is demonstrable during a post-payment audit.

Payers increasingly conduct retrospective record reviews for bone turnover marker claims. A chart that cannot show the treatment context at the time of the order invites a recoupment demand. That holds even if the initial claim was paid.

Modifiers used with 82523

Three modifiers are relevant to CPT code 82523 claims. Using the wrong modifier, or omitting a required one, produces a claim-level edit that delays payment or triggers a denial.

Codes commonly confused with 82523

Several adjacent CPT codes cover bone metabolism markers and are frequently ordered alongside or instead of CPT code 82523. Understanding the distinction prevents bundling errors and claim-level edits. Use the AAPC Codify CPT lookup to verify descriptors before submitting any multi-code lab claim.

Osteocalcin (83937) and collagen cross-links (82523) measure opposite sides of bone turnover: Formation versus resorption. Some payer policies address both markers, but payers do not automatically cover both on the same date. Check the applicable LCD or payer policy for multi-marker coverage rules before ordering.

Common denial reasons and how to fix them

Structured denial management workflows reduce the rework cost of 82523 rejections. Each denial reason below maps to a corrective action that can be applied during the pre-submission review or at the point of appeal. Track your denial codes to identify which category accounts for the most rework in your practice.

• Non-covered ICD-10 pairing: The diagnosis code submitted is not on the payer’s covered list for 82523. Fix: Cross-reference the covered code list or commercial policy before submission. Use the most specific supported ICD-10 code, and make sure the chart documents that diagnosis.
• Frequency limit exceeded: An 82523 claim for this patient was already paid within the payer’s window. Medicare follows the NCD 190.19 schedule, while some commercial policies use a 3-to-6-month window. Fix: Review remittance history before re-ordering. Issue an ABN if the test falls outside the covered schedule and the patient wants it anyway.
• Missing prior authorization: The plan required PA and none was obtained. Fix: Implement a PA flag in your lab order workflow that checks authorization status before the order is signed. PA denials are generally not appealable on medical grounds.
• No documented antiresorptive therapy: The chart does not confirm the patient is currently on a qualifying agent. Fix: Add a structured note field for the antiresorptive drug name, dose, and start date at every relevant encounter.
• CLIA laboratory not credentialed: The performing lab does not hold an appropriate CLIA certificate or is not recognized by the payer. Fix: Verify the reference lab’s CLIA status and payer credentialing before routing specimens.
• Screening-only indication: The order was placed without a confirmed diagnosis. The patient has a family history or risk factors but no documented osteoporosis or metabolic bone disease. Fix: Do not order 82523 until a diagnosis is confirmed and documented.

NCCI bundling and unit limits

The CMS National Correct Coding Initiative (NCCI) edits define which code pairs cannot be billed together without a modifier indicating a distinct service. NCCI edit files are updated quarterly. Verify any bundling relationship described here against the current CMS NCCI tool before submission.

CPT 82523 does not carry a widely published column-one/column-two edit pairing with osteocalcin (83937) or bone-specific alkaline phosphatase at the time of writing. Medically Unlikely Edits (MUEs) still cap the units of 82523 that can be reported per patient per date of service. Before reporting more than one unit, verify the MUE value in the CMS MUE table and the payer’s policy.

Key bundling considerations:

• More than one unit on the same date of service: Check the MUE value and the payer’s policy first. Use modifier 91 only if the payer confirms it applies, and document the clinical reason for each test.
• Panel coding: Some reference labs report bone turnover marker panels under an internal panel code. Confirm the CPT reported on the requisition is 82523 and not a proprietary panel code that may not be covered by your payer contracts.
• NCCI quarterly updates: The CMS NCCI Policy Manual and edit tables are published at CMS.gov. Subscribe to update notifications from your MAC to catch new bundling relationships before they generate claim edits.

How claims management software cuts 82523 denials

Bone turnover marker claims tend to fail for the same few reasons: A non-covered pairing, a test outside the schedule, or a plan nobody checked. Pabau, the practice management platform we build, includes claims management software that handles the billing side of these claims.

Before the specimen is drawn, your team can confirm the patient’s coverage with a real-time eligibility check. After the claim goes out, remittance data comes back into the same system.

• Real-time eligibility checks: Confirm the patient’s plan and benefits before the specimen is collected, so a coverage problem surfaces before the claim does.
• Superbill generation: Pabau generates superbill documentation with the procedure, diagnosis codes, and modifier fields in claim format. That cuts transcription errors between the order and the submitted claim.
• Electronic claims via Claim.MD: Pabau’s Claim.MD clearinghouse integration sends claims to thousands of US insurance payers.
• Electronic remittance: The same integration returns electronic remittance advice (ERA) with CARC denial-reason codes. Your team sees the denial category on a rejected 82523 claim and can correct it faster.

The result is fewer surprises at remittance. Coverage questions are settled before the draw, and denials arrive with a reason code your team can act on.

Get bone turnover marker claims paid first time

Pabau checks eligibility in real time, builds superbills, and brings Claim.MD remittance data back to the patient record. Your team spends less time reworking 82523 denials.

Book a demo

Conclusion

An 82523 claim is won or lost on the day the test is ordered. By the time the remittance comes back, the diagnosis, the treatment plan, and the test date are already fixed.

So time each order against NCD 190.19 for Medicare patients, and against the payer’s own policy for everyone else. A test that fits the schedule and names the antiresorptive plan is far easier to defend on audit.

The trade-off is a few minutes of checking before the specimen is drawn, which costs far less than reworking a denial. Book a demo to see how Pabau keeps eligibility checks, lab claims, and remittance data in one place.

Continue your research

Need to understand the clean-claim requirements before submitting? What makes a clean claim explains the seven elements every lab claim must satisfy to pass payer edits on the first pass.

Want to reduce overall claim rejection rates across your practice? How electronic remittance advice works shows how ERA data helps billing teams identify denial patterns and act on them faster.

Unsure how the 837P transaction connects your lab order to the payer? The 837 file explained covers the structure of the electronic claim transaction and where 82523 data appears in the file.

Frequently asked questions